Adherence and quality of life in children receiving rhGH treatment

• Published in: Archives de pédiatrie : organe officiel de la Société française de pédiatrie 2022-02, Vol.28 (8), p.28/8S3-28/8S8
• Main Authors: Gonzalez-Briceño, L., Viaud, M., Polak, M.
• Format: Article
• Language: English
• Subjects: Adherence; decision-making; Growth hormone; Quality of life; Shared; Short stature
• ISSN: 0929-693X; 1769-664X
• DOI: 10.1016/S0929-693X(22)00036-7

Short stature may have a major impact on quality of life (QoL), not only during adulthood but also during childhood. Treatment by growth hormone may induce improvement in QoL through height gain, as shown in recent articles, with an increase in general health-related and also height-specific QoL assessed by self-reports and parental reports. In a paper published by our team, we show altered general-health QoL in patients with very short stature (≤ –3 SD) and an improvement in general and height-specific scales in the complete population (≤ –2 SD) after one year of recombinant human growth hormone (rhGH) treatment, perceived both by children and their parents, with a moderate positive correlation with height gain. Adequate results in terms of height gain depend on different factors: the patient’s age, underlying condition for which rhGH is prescribed and dose of rhGH treatment, among others. Daily injections may cause a significant burden for the child and family, and may alter adequate adherence to treatment. Identifying positive and negative factors in the patient and in the healthcare providers–patient team and encouraging a shared decision-making process are important for improving the patient’s adherence to treatment. New long-acting forms of rhGH that will be available in the next few years may play an important part in improving treatment-related QoL and adherence to treatment. © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.